Allogeneic hematopoietic stem cell transplantation after CD19-directed CAR T-cell therapy in children and adults with B-cell acute lymphoblastic leukemia: a GoCART coalition study on behalf of the PDWP, ALWP, and CTIWP of the EBMT

Hematopoietic stem cell transplantation (HSCT) can rescue B-cell acute lymphoblastic leukemia (B-ALL) recurring after CD19-directed chimeric antigen receptor T cells (CAR19 T cells). However, in patients at high risk of relapse, the indication for and timing of consolidative HSCT are controversial. We retrieved data on 112 patients who received an HSCT at a median of 6.1 months after CAR19 T-cell infusion. Indication for subsequent HSCT were: (I) Rescue in 72 (64%) patients for disease recurrence; (II) Pre-emptive in 21 (19%) for loss of B-cell aplasia; (III) Consolidative in 19 patients (17%). The 2-year post-transplant Leukemia-Free Survival (LFS) was 54% and the 2-year cumulative incidence of relapse was 32%. Children had better LFS than adults (63% vs 38%). Older age was associated with inferior LFS (HR per 10-year increase 1.30; p= 0.01) and patients receiving a rescue HSCT had a significantly lower 2-year LFS (41%), compared to pre-emptive (74%) and consolidative HSCT (78%), respectively (p=0.002). Haploidentical donor was also associated with inferior LFS (HR: 2.21 95%CI: 1.15-4.25, p=0.02). This "real-world" study corroborates the need to identify patients at higher risk of relapse and optimization of strategies to improve outcome in patients with R/R B-ALL receiving CD19-directed CAR T cells.

Authors

Institutions

Publication Details

Journal
Haematologica
Published
2026-11-19
DOI
https://doi.org/10.3324/haematol.2026.301354
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Allogeneic hematopoietic stem cell transplantation after CD19-directed CAR T-cell therapy in children and adults with B-cell acute lymphoblastic leukemia: a GoCART coalition study on behalf of the PDWP, ALWP, and CTIWP of the EBMT

Shatha Farhan, Krzysztof Kałwak, Julio Delgado, Anne-Charlotte Teyssier et al.
Haematologica
CAR-T cell therapy research
article

Allogeneic hematopoietic stem cell transplantation after CD19-directed CAR T-cell therapy in children and adults with B-cell acute lymphoblastic leukemia: a GoCART coalition study on behalf of the PDWP, ALWP, and CTIWP of the EBMT

Shatha Farhan, Krzysztof Kałwak, Julio Delgado, Anne-Charlotte Teyssier, Júlia Marsal, Fabio Ciceri, Pere Barba, Sebastian Giebel, Valentín Ortiz‐Maldonado, Stephan Mielke, Yves P. Beguin, Giorgio Ottaviano, Arnon Nagler, Jacques‐Emmanuel Galimard, Anna Alonso‐Saladrigues, Samppa J. Ryhänen, Núria Martínez‐Cibrián, Adriana Balduzzi, Annalisa Ruggeri, Eva Michel, Soeren Lykke Petersen, Antonio Pérez Martínez, Fizza Imran, Jurgen Kuball, Andishe Attarbaschi, Susana Rives, Sowjana Vuyyala
article en

Abstract

Hematopoietic stem cell transplantation (HSCT) can rescue B-cell acute lymphoblastic leukemia (B-ALL) recurring after CD19-directed chimeric antigen receptor T cells (CAR19 T cells). However, in patients at high risk of relapse, the indication for and timing of consolidative HSCT are controversial. We retrieved data on 112 patients who received an HSCT at a median of 6.1 months after CAR19 T-cell infusion. Indication for subsequent HSCT were: (I) Rescue in 72 (64%) patients for disease recurrence; (II) Pre-emptive in 21 (19%) for loss of B-cell aplasia; (III) Consolidative in 19 patients (17%). The 2-year post-transplant Leukemia-Free Survival (LFS) was 54% and the 2-year cumulative incidence of relapse was 32%. Children had better LFS than adults (63% vs 38%). Older age was associated with inferior LFS (HR per 10-year increase 1.30; p= 0.01) and patients receiving a rescue HSCT had a significantly lower 2-year LFS (41%), compared to pre-emptive (74%) and consolidative HSCT (78%), respectively (p=0.002). Haploidentical donor was also associated with inferior LFS (HR: 2.21 95%CI: 1.15-4.25, p=0.02). This "real-world" study corroborates the need to identify patients at higher risk of relapse and optimization of strategies to improve outcome in patients with R/R B-ALL receiving CD19-directed CAR T cells.

Haematologica
Hospital Sant Joan de Déu Barcelona (ES), Mayo Clinic (US), University of Helsinki (FI), Henry Ford Health System (US), University of Liège (BE), Sheba Medical Center (IL), Hospital Universitario La Paz (ES), Copenhagen University Hospital (DK), Rigshospitalet (DK), Henry Ford Hospital (US), Karolinska Institutet (SE), University Medical Center Utrecht (NL), Wroclaw Medical University (PL), Centre Hospitalier Universitaire de Montpellier (FR), Azienda Ospedaliera San Gerardo (IT), Hospital Clínic de Barcelona (ES), St Anna Children's Hospital (AT), Vall d'Hebron Hospital Universitari (ES), IRCCS Ospedale San Raffaele (IT), Centre Hospitalier Universitaire de Liège (BE), The Maria Sklodowska-Curie National Research Institute of Oncology (PL), European Society for Blood and Marrow Transplantation (FR), Institut de Recerca Sant Joan de Déu (ES), University of Milano-Bicocca (IT)
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon